Haruka Itakura, MD, PhD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Pfizer
    Topic:
    Comparison of later-line treatment options for metastatic HER2+ breast cancer
    Date added:
    06/05/2025
    Date updated:
    06/05/2025
    Relationship end date:
    12/31/2025
Return to 5th Binaytara Precision Oncology Summit: Redefining Cancer Treatment with Molecular Targeted Strategies